This article describes the clinical data that led to approval of these B-cell receptor inhibitors for the treatment of CLL, and highlights newer agents in clinical development that target the same kinases as the currently available therapies.
Susan O’Brien, MD
ONCOLOGY talks with Dr. Susan O’Brien, professor in the department of leukemia at the MD Anderson Cancer Center. Dr. O’Brien will be one of the presenters at the upcoming ASCO session on therapies for chronic lymphocytic leukemia, and she gives us a preview of what some of the highlights of the session are likely to be, as well as some insights into her own work.
Commentary (O'Brien): Current Status of Monoclonal Antibody Therapy for Chronic Lymphocytic Leukemia
Dr. Nabhan and his coauthors
have written a comprehensive
review of the use of monoclonal
antibodies in the treatment of
chronic lymphocytic leukemia (CLL).
They have highlighted important
clinical trials with newer antibodies,
including apolizumab (Hu1D10,
Remitogen) and IDEC-152 (anti-
CD23). The authors concisely describe
the use of rituximab (Rituxan)
and alemtuzumab (Campath) as single
agents and in combination therapy.
Both antibodies have efficacy in
the treatment of CLL, but both have
limitations when used as single
Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and nontransplant treatment approaches to